Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

A New In Vivo Model to Study Protective Immunity to Zika Virus Infection in Mice With Intact Type I Interferon Signaling.

Nazerai L, Schøller AS, Rasmussen POS, Buus S, Stryhn A, Christensen JP, Thomsen AR.

Front Immunol. 2018 Mar 22;9:593. doi: 10.3389/fimmu.2018.00593. eCollection 2018.

2.

Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.

Bieling M, Tischer S, Kalinke U, Blasczyk R, Buus S, Maecker-Kolhoff B, Eiz-Vesper B.

Oncotarget. 2017 Dec 21;9(4):4737-4757. doi: 10.18632/oncotarget.23531. eCollection 2018 Jan 12.

3.

Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors.

Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, Kuranda K, Nigi L, Eugster A, Østerbye T, Maugein A, McLaren JE, Ladell K, Larger E, Beressi JP, Lissina A, Appay V, Davidson HW, Buus S, Price DA, Kuhn M, Bonifacio E, Battaglia M, Caillat-Zucman S, Dotta F, Scharfmann R, Kyewski B, Mallone R; ImMaDiab Study Group, Carel JC, Tubiana-Rufi N, Martinerie L, Poidvin A, JacqzAigrain E, Corvez L, Berruer V, Gautier JF, Baz B, Haddadi N, Andreelli F, Amouyal C, Jaqueminet S, Bourron O, Dasque E, Hartemann A, Lemoine-Yazigi A, Dubois-Laforgue D, Travert F, Feron M, Rolland P, Vignali V, Marre M, Chanson P, Briet C, Guillausseau PJ, Ait-Bachir L, Collet C, Beziaud F, Desforges-Bullet V, Petit-Aubert G, Christin-Maitre S, Fève B, Vatier C, Bourcigaux N, Lautridou C, Lahlou N, Bakouboula P, Elie C, Morel H, Treluyer JM, Gagnerault MC, Maillard C, Jones A.

Sci Immunol. 2018 Feb 2;3(20). pii: eaao4013. doi: 10.1126/sciimmunol.aao4013.

PMID:
29429978
4.

Improved methods for predicting peptide binding affinity to MHC class II molecules.

Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M.

Immunology. 2018 Jul;154(3):394-406. doi: 10.1111/imm.12889. Epub 2018 Feb 6.

PMID:
29315598
5.

Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations.

Malik A, Adland E, Laker L, Kløverpris H, Fardoos R, Roider J, Severinsen MC, Chen F, Riddell L, Edwards A, Buus S, Jooste P, Matthews PC, Goulder PJR.

PLoS One. 2017 Dec 12;12(12):e0189612. doi: 10.1371/journal.pone.0189612. eCollection 2017.

6.

Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P.

J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

7.

Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities.

Leitman EM, Palmer CD, Buus S, Chen F, Riddell L, Sims S, Klenerman P, Sáez-Cirión A, Walker BD, Hess PR, Altfeld M, Matthews PC, Goulder PJR.

PLoS One. 2017 Oct 11;12(10):e0184496. doi: 10.1371/journal.pone.0184496. eCollection 2017.

8.

Time-resolved in vivo dosimetry for source tracking in brachytherapy.

Johansen JG, Rylander S, Buus S, Bentzen L, Hokland SB, Søndergaard CS, With AKM, Kertzscher G, Tanderup K.

Brachytherapy. 2018 Jan - Feb;17(1):122-132. doi: 10.1016/j.brachy.2017.08.009. Epub 2017 Sep 22.

PMID:
28943129
9.

Needle migration and dosimetric impact in high-dose-rate brachytherapy for prostate cancer evaluated by repeated MRI.

Buus S, Lizondo M, Hokland S, Rylander S, Pedersen EM, Tanderup K, Bentzen L.

Brachytherapy. 2018 Jan - Feb;17(1):50-58. doi: 10.1016/j.brachy.2017.08.005. Epub 2017 Sep 19.

PMID:
28935450
10.

Low antigen dose formulated in CAF09 adjuvant Favours a cytotoxic T-cell response following intraperitoneal immunization in Göttingen minipigs.

Overgaard NH, Frøsig TM, Jakobsen JT, Buus S, Andersen MH, Jungersen G.

Vaccine. 2017 Oct 9;35(42):5629-5636. doi: 10.1016/j.vaccine.2017.08.057. Epub 2017 Sep 5.

11.

HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.

Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha A, Walker BD, Martin J, Deeks S, Wolinsky SM, Martinson J, Martin M, Qi Y, Sáez-Cirión A, Yang OO, Matthews PC, Carrington M, Goulder PJR.

J Virol. 2017 Oct 27;91(22). pii: e00544-17. doi: 10.1128/JVI.00544-17. Print 2017 Nov 15.

12.

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW, Mallal S, Phillips EJ.

Sci Rep. 2017 Aug 17;7(1):8653. doi: 10.1038/s41598-017-08876-0.

13.

Vertebral Myeloma Mimicking Prostatic Carcinoma Metastasis in 68Ga-PSMA PET/CT.

Merrild EH, Baerentzen S, Bouchelouche K, Buus S.

Clin Nucl Med. 2017 Oct;42(10):790-792. doi: 10.1097/RLU.0000000000001773.

PMID:
28737577
14.

Structural Elements Recognized by Abacavir-Induced T Cells.

Yerly D, Pompeu YA, Schutte RJ, Eriksson KK, Strhyn A, Bracey AW, Buus S, Ostrov DA.

Int J Mol Sci. 2017 Jul 7;18(7). pii: E1464. doi: 10.3390/ijms18071464.

15.

Prediction and in vitro verification of potential CTL epitopes conserved among PRRSV-2 strains.

Welner S, Nielsen M, Rasmussen M, Buus S, Jungersen G, Larsen LE.

Immunogenetics. 2017 Oct;69(10):689-702. doi: 10.1007/s00251-017-1004-8. Epub 2017 Jun 7.

16.

HIV-1 adaptation to NK cell-mediated immune pressure.

Elemans M, Boelen L, Rasmussen M, Buus S, Asquith B.

PLoS Pathog. 2017 Jun 5;13(6):e1006361. doi: 10.1371/journal.ppat.1006361. eCollection 2017 Jun.

17.

Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.

Kongsgaard M, Bassi MR, Rasmussen M, Skjødt K, Thybo S, Gabriel M, Hansen MB, Christensen JP, Thomsen AR, Buus S, Stryhn A.

Sci Rep. 2017 Apr 6;7(1):662. doi: 10.1038/s41598-017-00798-1.

18.

Dosimetric impact of contouring and needle reconstruction uncertainties in US-, CT- and MRI-based high-dose-rate prostate brachytherapy treatment planning.

Rylander S, Buus S, Pedersen EM, Bentzen L, Tanderup K.

Radiother Oncol. 2017 Apr;123(1):125-132. doi: 10.1016/j.radonc.2017.01.007. Epub 2017 Mar 8.

PMID:
28284493
19.

ArrayPitope: Automated Analysis of Amino Acid Substitutions for Peptide Microarray-Based Antibody Epitope Mapping.

Hansen CS, Østerbye T, Marcatili P, Lund O, Buus S, Nielsen M.

PLoS One. 2017 Jan 17;12(1):e0168453. doi: 10.1371/journal.pone.0168453. eCollection 2017.

20.

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.

Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjær SB, Pascal V, León IR, Gudme CN, Buus S, Sauna ZE.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag1286. doi: 10.1126/scitranslmed.aag1286.

PMID:
28077675
21.

HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer+ Gag-Specific CD4+ T Cells in Chronic Clade C HIV-1 Infection.

Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD, Ndung'u T, Ndhlovu ZM.

J Virol. 2017 Mar 13;91(7). pii: e02477-16. doi: 10.1128/JVI.02477-16. Print 2017 Apr 1.

22.

Expanding specificity of class I restricted CD8+ T cells for viral epitopes following multiple inoculations of swine with a human adenovirus vectored foot-and-mouth disease virus (FMDV) vaccine.

Pedersen LE, Patch JR, Kenney M, Glabman RA, Nielsen M, Jungersen G, Buus S, Golde WT.

Vet Immunol Immunopathol. 2016 Nov 15;181:59-67. doi: 10.1016/j.vetimm.2016.07.012. Epub 2016 Jul 27.

PMID:
27498407
23.

Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity.

Rasmussen M, Fenoy E, Harndahl M, Kristensen AB, Nielsen IK, Nielsen M, Buus S.

J Immunol. 2016 Aug 15;197(4):1517-24. doi: 10.4049/jimmunol.1600582. Epub 2016 Jul 8.

24.

Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer.

Buus S, Rylander S, Hokland S, Søndergaard CS, Pedersen EM, Tanderup K, Bentzen L.

Brachytherapy. 2016 Jul-Aug;15(4):426-434. doi: 10.1016/j.brachy.2016.03.011. Epub 2016 May 21.

PMID:
27220699
25.

Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.

Bassi MR, Larsen MA, Kongsgaard M, Rasmussen M, Buus S, Stryhn A, Thomsen AR, Christensen JP.

PLoS Negl Trop Dis. 2016 Feb 17;10(2):e0004464. doi: 10.1371/journal.pntd.0004464. eCollection 2016 Feb.

26.

Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, Ramchandani MS, Johnston C, Buus S, Redwood AJ, White KD, Mallal SA, Phillips EJ, Posavad CM, Wald A, Koelle DM.

J Immunol. 2016 Mar 1;196(5):2205-2218. doi: 10.4049/jimmunol.1502366. Epub 2016 Jan 25.

27.

Immunogenicity of HLA Class I and II Double Restricted Influenza A-Derived Peptides.

Pedersen SR, Christensen JP, Buus S, Rasmussen M, Korsholm KS, Nielsen M, Claesson MH.

PLoS One. 2016 Jan 5;11(1):e0145629. doi: 10.1371/journal.pone.0145629. eCollection 2016.

28.

HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.

Thuring C, Follin E, Geironson L, Freyhult E, Junghans V, Harndahl M, Buus S, Paulsson KM.

Br J Cancer. 2015 Dec 1;113(11):1640. doi: 10.1038/bjc.2015.387. No abstract available.

29.

A combined prediction strategy increases identification of peptides bound with high affinity and stability to porcine MHC class I molecules SLA-1*04:01, SLA-2*04:01, and SLA-3*04:01.

Pedersen LE, Rasmussen M, Harndahl M, Nielsen M, Buus S, Jungersen G.

Immunogenetics. 2016 Feb;68(2):157-65. doi: 10.1007/s00251-015-0883-9. Epub 2015 Nov 14.

PMID:
26572135
30.

A modern approach for epitope prediction: identification of foot-and-mouth disease virus peptides binding bovine leukocyte antigen (BoLA) class I molecules.

Pandya M, Rasmussen M, Hansen A, Nielsen M, Buus S, Golde W, Barlow J.

Immunogenetics. 2015 Nov;67(11-12):691-703.

PMID:
26496773
31.

Establishing the pig as a large animal model for vaccine development against human cancer.

Overgaard NH, Frøsig TM, Welner S, Rasmussen M, Ilsøe M, Sørensen MR, Andersen MH, Buus S, Jungersen G.

Front Genet. 2015 Sep 15;6:286. doi: 10.3389/fgene.2015.00286. eCollection 2015.

32.

Automated High-Throughput Mapping of Linear B-Cell Epitopes Using a Statistical Analysis of High-Density Peptide Microarray Data.

Østerbye T, Buus S.

Methods Mol Biol. 2015;1348:215-28. doi: 10.1007/978-1-4939-2999-3_19.

PMID:
26424275
33.

Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification.

Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M.

Immunogenetics. 2015 Nov;67(11-12):641-50. doi: 10.1007/s00251-015-0873-y. Epub 2015 Sep 29.

34.

Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point.

Ndhlovu ZM, Kamya P, Mewalal N, Kløverpris HN, Nkosi T, Pretorius K, Laher F, Ogunshola F, Chopera D, Shekhar K, Ghebremichael M, Ismail N, Moodley A, Malik A, Leslie A, Goulder PJ, Buus S, Chakraborty A, Dong K, Ndung'u T, Walker BD.

Immunity. 2015 Sep 15;43(3):591-604. doi: 10.1016/j.immuni.2015.08.012. Epub 2015 Sep 8.

35.

HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.

Thuring C, Follin E, Geironson L, Freyhult E, Junghans V, Harndahl M, Buus S, Paulsson KM.

Br J Cancer. 2015 Sep 15;113(6):952-62. doi: 10.1038/bjc.2015.297. Epub 2015 Aug 27. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1640.

36.

The influence of a rectal ultrasound probe on the separation between prostate and rectum in high-dose-rate brachytherapy.

Rylander S, Buus S, Bentzen L, Pedersen EM, Tanderup K.

Brachytherapy. 2015 Sep-Oct;14(5):711-7. doi: 10.1016/j.brachy.2015.06.001. Epub 2015 Jul 9.

PMID:
26164752
37.

Disease progression despite protective HLA expression in an HIV-infected transmission pair.

Brener J, Gall A, Batorsky R, Riddell L, Buus S, Leitman E, Kellam P, Allen T, Goulder P, Matthews PC.

Retrovirology. 2015 Jun 30;12:55. doi: 10.1186/s12977-015-0179-z.

38.

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity.

Metushi IG, Wriston A, Banerjee P, Gohlke BO, English AM, Lucas A, Moore C, Sidney J, Buus S, Ostrov DA, Mallal S, Phillips E, Shabanowitz J, Hunt DF, Preissner R, Peters B.

PLoS One. 2015 May 29;10(5):e0124878. doi: 10.1371/journal.pone.0124878. eCollection 2015.

39.

Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes.

Culina S, Gupta N, Boisgard R, Afonso G, Gagnerault MC, Dimitrov J, Østerbye T, Justesen S, Luce S, Attias M, Kyewski B, Buus S, Wong FS, Lacroix-Desmazes S, Mallone R.

Diabetes. 2015 Oct;64(10):3532-42. doi: 10.2337/db15-0024. Epub 2015 Apr 27.

40.

CD8+ TCR Bias and Immunodominance in HIV-1 Infection.

Kløverpris HN, McGregor R, McLaren JE, Ladell K, Harndahl M, Stryhn A, Carlson JM, Koofhethile C, Gerritsen B, Keşmir C, Chen F, Riddell L, Luzzi G, Leslie A, Walker BD, Ndung'u T, Buus S, Price DA, Goulder PJ.

J Immunol. 2015 Jun 1;194(11):5329-45. doi: 10.4049/jimmunol.1400854. Epub 2015 Apr 24.

41.

Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding.

Chappell P, Meziane el K, Harrison M, Magiera Ł, Hermann C, Mears L, Wrobel AG, Durant C, Nielsen LL, Buus S, Ternette N, Mwangi W, Butter C, Nair V, Ahyee T, Duggleby R, Madrigal A, Roversi P, Lea SM, Kaufman J.

Elife. 2015 Apr 10;4:e05345. doi: 10.7554/eLife.05345.

42.

A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape.

Kløverpris HN, Cole DK, Fuller A, Carlson J, Beck K, Schauenburg AJ, Rizkallah PJ, Buus S, Sewell AK, Goulder P.

Retrovirology. 2015 Feb 20;12:20. doi: 10.1186/s12977-015-0149-5.

43.

Abacavir-reactive memory T cells are present in drug naïve individuals.

Lucas A, Lucas M, Strhyn A, Keane NM, McKinnon E, Pavlos R, Moran EM, Meyer-Pannwitt V, Gaudieri S, D'Orsogna L, Kalams S, Ostrov DA, Buus S, Peters B, Mallal S, Phillips E.

PLoS One. 2015 Feb 12;10(2):e0117160. doi: 10.1371/journal.pone.0117160. eCollection 2015.

44.

CD8+ T cells complement antibodies in protecting against yellow fever virus.

Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjødt K, Finsen B, Stryhn A, Buus S, Christensen JP, Thomsen AR.

J Immunol. 2015 Feb 1;194(3):1141-53. doi: 10.4049/jimmunol.1402605. Epub 2014 Dec 24.

45.

Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires.

Bergseng E, Dørum S, Arntzen MØ, Nielsen M, Nygård S, Buus S, de Souza GA, Sollid LM.

Immunogenetics. 2015 Feb;67(2):73-84. doi: 10.1007/s00251-014-0819-9. Epub 2014 Dec 12.

46.

T cell-mediated hypersensitivity reactions to drugs.

Pavlos R, Mallal S, Ostrov D, Buus S, Metushi I, Peters B, Phillips E.

Annu Rev Med. 2015;66:439-54. doi: 10.1146/annurev-med-050913-022745. Epub 2014 Oct 27. Review.

47.

Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule.

Rasmussen M, Harndahl M, Stryhn A, Boucherma R, Nielsen LL, Lemonnier FA, Nielsen M, Buus S.

J Immunol. 2014 Nov 15;193(10):4790-802. doi: 10.4049/jimmunol.1401689. Epub 2014 Oct 13.

48.

Characterization of binding specificities of bovine leucocyte class I molecules: impacts for rational epitope discovery.

Hansen AM, Rasmussen M, Svitek N, Harndahl M, Golde WT, Barlow J, Nene V, Buus S, Nielsen M.

Immunogenetics. 2014 Dec;66(12):705-18. doi: 10.1007/s00251-014-0802-5. Epub 2014 Sep 4.

49.

Dataset size and composition impact the reliability of performance benchmarks for peptide-MHC binding predictions.

Kim Y, Sidney J, Buus S, Sette A, Nielsen M, Peters B.

BMC Bioinformatics. 2014 Jul 14;15:241. doi: 10.1186/1471-2105-15-241.

50.

Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load.

Kløverpris HN, McGregor R, McLaren JE, Ladell K, Stryhn A, Koofhethile C, Brener J, Chen F, Riddell L, Graziano L, Klenerman P, Leslie A, Buus S, Price DA, Goulder P.

AIDS. 2014 Sep 10;28(14):2007-21.

Supplemental Content

Support Center